First Header Logo Second Header Logo

Connection

Karl-Erik Andersson to Prostate

This is a "connection" page, showing publications Karl-Erik Andersson has written about Prostate.
Connection Strength

2.248
  1. Andersson KE. Intraprostatic injections for lower urinary tract symptoms treatment. Curr Opin Urol. 2015 Jan; 25(1):12-8.
    View in: PubMed
    Score: 0.421
  2. Zarifpour M, Nomiya M, Sawada N, Andersson KE. Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. Prostate. 2015 Feb 15; 75(3):233-41.
    View in: PubMed
    Score: 0.415
  3. Sievert KD, Hennenlotter J, Dillenburg T, Toomey P, Wöllner J, Zweers P, Pannek J, Andersson KE, Amend B. Extended periprostatic nerve distributions on the prostate surface confirmed using diffusion tensor imaging. BJU Int. 2019 06; 123(6):995-1004.
    View in: PubMed
    Score: 0.140
  4. Lombardo R, Andersson KE, Tubaro A, De Nunzio C. Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment. Minerva Urol Nefrol. 2018 Dec; 70(6):570-578.
    View in: PubMed
    Score: 0.137
  5. Peng Z, Andersson K, Lindholm J, Dethlefsen O, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material. PLoS One. 2016; 11(1):e0145545.
    View in: PubMed
    Score: 0.113
  6. Kunit T, Gratzke C, Schreiber A, Strittmatter F, Waidelich R, Rutz B, Loidl W, Andersson KE, Stief CG, Hennenberg M. Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate. Am J Physiol Renal Physiol. 2014 Oct 01; 307(7):F823-32.
    View in: PubMed
    Score: 0.102
  7. Hennenberg M, Miljak M, Herrmann D, Strittmatter F, Walther S, Rutz B, Hocaoglu Y, Kunit T, Schreiber A, Andersson KE, Stief CG, Gratzke C. The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle. Am J Physiol Renal Physiol. 2013 Nov 15; 305(10):F1383-90.
    View in: PubMed
    Score: 0.096
  8. Andersson KE. Treatment of lower urinary tract symptoms: agents for intraprostatic injection. Scand J Urol. 2013 Apr; 47(2):83-90.
    View in: PubMed
    Score: 0.092
  9. Hennenberg M, Strittmatter F, Beckmann C, Rutz B, Füllhase C, Waidelich R, Montorsi F, Hedlund P, Andersson KE, Stief CG, Gratzke C. Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle. PLoS One. 2012; 7(11):e50904.
    View in: PubMed
    Score: 0.091
  10. Kurizaki Y, Ishizuka O, Imamura T, Ishikawa M, Ichino M, Ogawa T, Nishizawa O, Andersson KE. Relationship between expression of ß3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Neurourol Urodyn. 2013 Jan; 32(1):88-91.
    View in: PubMed
    Score: 0.088
  11. Hennenberg M, Strittmatter F, Walther S, Hedlund P, Andersson KE, Stief CG, Schlenker B, Gratzke C. a1-adrenoceptor activation induces phosphorylation of ß2-adrenoceptors in human prostate tissue. BJU Int. 2011 Sep; 108(6):922-8.
    View in: PubMed
    Score: 0.081
  12. Bauer RM, Strittmatter F, Gratzke C, Göttinger J, Schlenker B, Reich O, Stief CG, Hedlund P, Andersson KE, Hennenberg M. Coupling of a1-adrenoceptors to ERK1/2 in the human prostate. Urol Int. 2011; 86(4):427-33.
    View in: PubMed
    Score: 0.080
  13. Strittmatter F, Gratzke C, Weinhold P, Steib CJ, Hartmann AC, Schlenker B, Andersson KE, Hedlund P, Stief CG, Hennenberg M. Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms. Eur J Pharmacol. 2011 Jan 15; 650(2-3):650-5.
    View in: PubMed
    Score: 0.079
  14. Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007 Oct; 26(6 Suppl):948-54.
    View in: PubMed
    Score: 0.064
  15. Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn. 2007 Oct; 26(6 Suppl):928-33.
    View in: PubMed
    Score: 0.064
  16. Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007 Jul; 4(7):368-78.
    View in: PubMed
    Score: 0.063
  17. Waldkirch ES, Uckert S, Langnäse K, Richter K, Jonas U, Wolf G, Andersson KE, Stief CG, Hedlund P. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol. 2007 Aug; 52(2):495-501.
    View in: PubMed
    Score: 0.061
  18. Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol. 2002 Apr; 19(6):390-6.
    View in: PubMed
    Score: 0.044
  19. Gratzke C, Weinhold P, Reich O, Seitz M, Schlenker B, Stief CG, Andersson KE, Hedlund P. Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. Eur Urol. 2010 May; 57(5):902-10.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.